Fulvestrant plus anastrozole extends lives of women with advanced HR+ breast cancer

(SWOG) Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, fulvestrant and anastrozole, compared with treatment with anastrozole alone, according to results of a SWOG Cancer Research Network study appearing in the New England Journal of Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news